LAZCLUZE®
(lazertinib)
LAZCLUZE® (lazertinib)
LAZCLUZE - pivotal clinical trial publications
MARIPOSA
Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC [published online ahead of print June 26, 2024]. N Engl J Med. 2024. doi:10.1056/nejmoa2403614.
Cho BC, Lu S, Felip E, et al. Supplementary Appendix for: Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC [published online ahead of print June 26, 2024]. N Engl J Med. 2024. doi:10.1056/nejmoa2403614.
Plain language summaries of pivotal clinical trials
MARIPOSA
Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2024.18(6):639-647.